Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment options with very low response rate. Lung cancer is the most common cause of cancer death worldwide. Therapies that target driver gene mutations (e.g. EGFR, ALK, ROS1) and checkpoint inhibitors such anti-PD-1 and...
Main Authors: | Akram Alwithenani, Drew Bethune, Mathieu Castonguay, Arik Drucker, Gordon Flowerdew, Marika Forsythe, Daniel French, John Fris, Wenda Greer, Harry Henteleff, Mary MacNeil, Paola Marignani, Wojciech Morzycki, Madelaine Plourde, Stephanie Snow, Paola Marcato, Zhaolin Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0251080 |
Similar Items
-
Molecular profiling of non-small cell lung cancer.
by: Marika L Forsythe, et al.
Published: (2020-01-01) -
Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
by: Weixian Hu
Published: (2020-01-01) -
PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
by: Chiao-En Wu, et al.
Published: (2020-01-01) -
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
by: Marius Ilie, et al.
Published: (2017-01-01) -
Selection of stable reference genes for RT-qPCR in Rhodococcus opacus PD630
by: Drew M. DeLorenzo, et al.
Published: (2018-04-01)